Psychedelic solution for depression: British drug firm starts clinical trials of new treatment that sends patients on a hallucinogenic trip

  • Small Pharma is carrying out clinical trials of a drug based on chemical DMT
  • It is a psychedelic found in plants and animals that produces hallucinations 
  • The clinical trials aim to see if it can work with therapy to treat severe depression
  • Assuming it works it could be on the market within the next six years, they said

A powerful hallucinogenic drug that has been used in shamanic rituals is being trialled by a British firm as a potential cure for depression

Small Pharma will give volunteers suffering from depression DMT, a hallucinogenic tryptamine with similar psychedelic effects to LSD and magic mushrooms.

The developers hope the drug will help a ‘significant number’ of people who don’t currently respond to conventional treatments or medication for depression

‘The science was moving forward and we were discovering new things about known compounds we didn’t know before, and I thought that was the perfect environment we could operate in,’

said Rands.


About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: